HIGHLIGHTS
- who: Sophie Barillé-Nion and colleagues from the Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERMU1232, SIRIC ILIAD, Nantes, France have published the research work: Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?, in the Journal: (JOURNAL)
- future: This suggests that BCL-2 inhibition may leave intact some anti-tumoral immune cells but further dedicated analysis exploring the effects of the whole BH3 mimetic arsenal on human immunocompetent models is required.
SUMMARY
Upon overwhelming stress conditions, cells . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.